-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The central nervous system (Central Nervous System) consists of the brain and spinal cord (the central part of the various reflex arcs) that is a very important main part of the human nervous system.
And central nervous system diseases, refers to a group of neurological disorders affecting the structure or function of the brain or spinal cord, including neurodegenerative diseases, functional disorders, structural disorders, central nervous system infections and demyelination diseases.
Among the total global consumption of central nervous nerve drugs, the United States accounted for 49%, Europe and Japan accounted for 26% and 9%, respectively, China accounted for only 3% of the total global consumption, which shows that the domestic central nervous nerve drug industry and foreign countries are still in their infancy.
recent years, as the prevalence of central nervous system diseases in China has continued to rise, the market demand for related medicines has also begun to show an upward trend.
data show that China's sales of central nervous system medicines have increased from 144 billion yuan in 2015 to 204.3 billion yuan in 2019, with a compound annual growth rate of 9.1%, and are expected to grow at a compound annual rate of 4.6% from 2020 to 2024, and will grow at a faster rate than the international rate, reaching 250.9 billion yuan in 2024.
It is understood that in order to seize the Chinese market, the international central nerve pharmaceutical giants have targeted the Chinese pharmaceutical market, Lilly, GlaxoSmithKline, Xi'an Yangsen, Lingbei are increasingly importance to the Chinese market.
Russi, like Lilly, will launch 40 new drugs and new adaptations in China over the next 7 to 10 years, focusing on neurodegenerative diseases, tumors, immunity, diabetes and pain, and Sanofi plans to accelerate innovation in the Chinese market, focusing on research and development in specialty medicines, including rare blood diseases, tumors, immunologies, neurological diseases and rare diseases.
fact, there is a reason why multinational pharmaceutical companies are so in love with the central nervous market.
according to industry insiders, at present, China's domestic pharmaceutical companies can independently develop and produce a few central nerve drugs, while Lingbei, GlaxoSmithKline and other central nerve pharmaceutical industry has many years of research and development experience and a number of successful products, which is foreign pharmaceutical companies to seize the innity of China's neuropharmaceutical market.
, in recent years, with the expansion of the domestic central nervous drug market, domestic pharmaceutical companies have also begun to add code layout.
Such as Enhua Pharmaceuticals is the national fixed-point anaesthetic and psychopharmaceutical production base, but also an important domestic manufacturers and distributors of central nervous system drugs, but also a focus on the central nervous system drug research and development and production of pharmaceutical enterprises.
through years of accumulation, it has a very rich product line, and formed a unique core competitiveness.
At present, Enhua Pharmaceuticals in the central nervous drug industry sub-sectors of anesthesia, spirit, nerves have a heavy product layout, right metotomidin (anesthesia), propofol (anesthesia), hydrochloric acid ethyl quether injection (anaesthetic), doloxitin (psycho), alequino (psycho), chilacetone (psycho) and other products sales have been stable growth in recent years.
, Howson Pharmaceuticals, as China's leading innovative pharmaceutical group, is also the domestic central nervous system and anti-tumor drug research and development and production of leading enterprises.
its drugs cover the central nervous system, anti-tumor, anti-infection, diabetes, digestive tract and cardiovascular six areas, and strategically focus on the top four areas.
, in the central nervous system, Henson Pharmaceuticals is mainly selling two products: Olanin and Ameinen.
2018 sales, Henson Pharmaceuticals is China's largest psychiatric pharmaceutical company with a market share of 9.2%, and has been a leading market leader in China's psychopharmaceutical market since 2014.
recent years, Henson has continued to expand its sales network.
by the end of 2018, its sales team had reached 4,500 people, covering 1,900 level 3 hospitals and more than 5,000 level 2 hospitals and other medical institutions, with full coverage in both the central nervous system and oncology.
The industry expects that China's central nervous system pharmaceutical market will continue to grow in the future, driven by an increase in the number of patients, an increase in per capita disposable income, the launch of new products, and the expansion of central nervous system drug adaptation.
.